logo-loader
viewMidatech Pharma PLC

Unnamed pharma giant to trial Midatech’s Q-Sphera drug delivery technology

Results from a study of Midatech’s acromegaly and carcinoid cancer drug, MTD201, earlier in the year showed that Q-Sphera works as planned

scientist in lab
Q-Sphera allows drugs to be delivered into the body over a prolonged period of time

A “leading global pharmaceutical corporation” has signed a deal with Midatech Pharma Plc (LON:MTPH) that will see it evaluate the latter’s Q-Sphera drug delivery platform.

Q-Sphera allows drug compounds to be released into the body in a “highly controlled manner” over a prolonged period of time; potentially from a few days to up to six months.

Under the collaboration agreement, the unnamed partner will conduct a feasibility program using the Q-Sphera technology. No financial terms have been disclosed.

READ: Midatech delighted with first-in-human data for MTD201

A study of Midatech’s MTD201 acromegaly treatment earlier this year provided a major validation of the platform, with results showing two things: that MTD201 was possibly a better treatment than rival one developed by Novartis but also that Q-Sphera works.

“We are delighted to announce this partnership with a leading global pharmaceutical corporation,” said chief executive Craig Cook.

“This marks another important step in the development of our impressive Q-Sphera technology, after the positive clinical 'proof of concept' first-in-human study earlier this year in carcinoid cancer and acromegaly.”

He added: “Together with partnerships such as the one being announced we are focused on increasing our traction in the sustained delivery market, where we hope to establish Q-Sphera as the leading platform.”

Quick facts: Midatech Pharma PLC

Price: 2.35 GBX

AIM:MTPH
Market: AIM
Market Cap: £11.04 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Midatech Pharma PLC named herein, including the promotion by the Company of Midatech Pharma PLC in any Content on the Site, the Company...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Investor Update: accesso Technology announces deal with The New York...

Top stories from the Proactive Investors UK newsroom: accesso Technology Group PLC (LON:ACSO) has signed a three-year partnership with The New York Botanical Garden (NYBG) to supply its Passport, Siriusware and Ingresso products. Based near The Bronx, the NYBG attracts over 1mln visitors...

on 13/6/19

2 min read